{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:55:13Z","timestamp":1781513713014,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05093-3","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:55:51Z","timestamp":1771563351000},"page":"11629-11642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series"],"prefix":"10.1007","volume":"399","author":[{"given":"Mahmoud Gamal","family":"Algammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R. S. B.","family":"Elgmmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman Mohamed Yassein","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Mostafa Mohammed","family":"Marouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mohamed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Bahaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khlood Mohammad","family":"Aldossary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Mahmoud Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"1","key":"5093_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02770-2","volume":"23","author":"Y Abdel-Hafez","year":"2022","unstructured":"Abdel-Hafez Y, Siaj H, Janajri M, Abu-Baker Y, Nazzal Z, Hamdan Z et al (2022) Tolerability and epidemiology of nephrotoxicity associated with conventional amphotericin B therapy: a retrospective study in tertiary care centers in Palestine. BMC Nephrol 23(1):132","journal-title":"BMC Nephrol"},{"issue":"4","key":"5093_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jof10040278","volume":"10","author":"K Akinosoglou","year":"2024","unstructured":"Akinosoglou K, Rigopoulos EA, Papageorgiou D, Schinas G, Polyzou E, Dimopoulou E et al (2024) Amphotericin B in the era of new antifungals: where will it stand? J Fungi 10(4):278","journal-title":"J Fungi"},{"key":"5093_CR3","doi-asserted-by":"crossref","unstructured":"Antachopoulos C, Petraitiene R, Roilides E, Walsh TJ (2023) Mucormycosis. Diagnosis and treatment of fungal infections. Springer, pp 221\u201335","DOI":"10.1007\/978-3-031-35803-6_14"},{"issue":"11","key":"5093_CR4","first-page":"004914","volume":"11","author":"OA Barbosa","year":"2024","unstructured":"Barbosa OA, Sousa Eliseu, do Amaral J, Furtado GP, da Silva VCF, de Alencar Isabele M, de Freitas KA (2024) Fungal necrotizing fasciitis due to mucormycosis following contaminated substance inoculation: a report of two cases. Eur J Case Rep Intern Med 11(11):004914","journal-title":"Eur J Case Rep Intern Med"},{"issue":"4","key":"5093_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2023.101438","volume":"33","author":"F Bongomin","year":"2023","unstructured":"Bongomin F, Ekeng BE, Kwizera R, Salmanton-Garc\u00eda J, Kibone W, van Rhijn N et al (2023) Fungal diseases in Africa: closing the gaps in diagnosis and treatment through implementation research and advocacy. J Med Mycol 33(4):101438","journal-title":"J Med Mycol"},{"issue":"1","key":"5093_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","volume":"10","author":"FB Cavassin","year":"2021","unstructured":"Cavassin FB, Ba\u00fa-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F (2021) Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther 10(1):115\u2013147","journal-title":"Infect Dis Ther"},{"issue":"10","key":"5093_CR7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14787210.2023.2257895","volume":"21","author":"A Chakrabarti","year":"2023","unstructured":"Chakrabarti A, Patel AK, Soman R, Todi S (2023) Overcoming clinical challenges in the management of invasive fungal infections in low-and middle-income countries (LMIC). Expert Rev Anti-Infect Ther 21(10):1057\u20131070","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"5093_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12281-019-0337-1","volume":"13","author":"S Challa","year":"2019","unstructured":"Challa S (2019) Mucormycosis: pathogenesis and pathology. Curr Fungal Infect Rep 13(1):11\u201320","journal-title":"Curr Fungal Infect Rep"},{"issue":"8","key":"5093_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081266","volume":"10","author":"P Chandley","year":"2022","unstructured":"Chandley P, Subba P, Rohatgi S (2022) COVID-19-associated mucormycosis: a matter of concern amid the SARS-CoV-2 pandemic. Vaccines 10(8):1266","journal-title":"Vaccines"},{"key":"5093_CR10","doi-asserted-by":"crossref","unstructured":"Chen S-A, Slavin MA (2021) Management of Mucorales infections in transplant patients. Emerging Transplant Infections: Clinical Challenges and Implications. Springer, pp 1109\u201338","DOI":"10.1007\/978-3-030-25869-6_45"},{"issue":"12","key":"5093_CR11","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19(12):e405\u2013e421","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5093_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.idc.2024.11.008","volume":"39","author":"MM Czech","year":"2025","unstructured":"Czech MM, Cuellar-Rodriguez J (2025) Mucormycosis. Infect Dis Clin North Am 39(1):121\u2013144","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"5093_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/myc.12283","volume":"58","author":"DR Falci","year":"2015","unstructured":"Falci DR, da Rosa FB, Pasqualotto AC (2015) Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real\u2010life study. Mycoses 58(2):104\u2013112","journal-title":"Mycoses"},{"issue":"1","key":"5093_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13443-3","volume":"12","author":"S Farghly Youssif","year":"2022","unstructured":"Farghly Youssif S, Abdelrady MM, Thabet AA, Abdelhamed MA, Gad MOA, Abu-Elfatth AM et al (2022) COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma. Sci Rep 12(1):10494","journal-title":"Sci Rep"},{"issue":"4","key":"5093_CR15","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1097\/SCS.0000000000006191","volume":"31","author":"B Galletti","year":"2020","unstructured":"Galletti B, Freni F, Meduri A, Oliverio GW, Signorino GA, Perroni P et al (2020) Rhino-orbito-cerebral mucormycosis in diabetic disease mucormycosis in diabetic disease. J Craniofac Surg 31(4):e321\u2013e324","journal-title":"J Craniofac Surg"},{"issue":"2","key":"5093_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11046-021-00528-2","volume":"186","author":"D Garg","year":"2021","unstructured":"Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A et al (2021) Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 186(2):289\u2013298","journal-title":"Mycopathologia"},{"issue":"7","key":"5093_CR17","first-page":"67","volume":"22","author":"U Gupta","year":"2022","unstructured":"Gupta U, Paliwal D, Rawat S (2022) Mucormycosis in India: pathophysiology and perspectives on treatment and management. Infectious Disorders-Drug TargetsDisorders 22(7):67\u201375","journal-title":"Infectious Disorders-Drug TargetsDisorders"},{"issue":"9","key":"5093_CR18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"RJ Hamill","year":"2013","unstructured":"Hamill RJ (2013) Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73(9):919\u2013934","journal-title":"Drugs"},{"issue":"1","key":"5093_CR19","volume":"2723","author":"T Jain","year":"2023","unstructured":"Jain T, Shrivastava P, Rai P, Paul S, Sharma RK (2023) Mucormycosis: a rare fungal infection that emerged as epidemic. Recent advances in material science and computational techniques (RAMSACT) 2723(1):020001","journal-title":"RECENT ADVANCES IN MATERIAL SCIENCE AND COMPUTATIONAL TECHNIQUES (RAMSACT)"},{"issue":"1","key":"5093_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","volume":"25","author":"W Jeong","year":"2019","unstructured":"Jeong W, Keighley C, Wolfe R, Lee WL, Slavin M, Kong D et al (2019) The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 25(1):26\u201334","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5093_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jof7040298","volume":"7","author":"TM John","year":"2021","unstructured":"John TM, Jacob CN, Kontoyiannis DP (2021) When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 7(4):298","journal-title":"J Fungi"},{"issue":"2","key":"5093_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12281-023-00463-3","volume":"17","author":"F Lamoth","year":"2023","unstructured":"Lamoth F (2023) Novel approaches in the management of mucormycosis. Curr Fungal Infect Rep 17(2):98\u2013107","journal-title":"Curr Fungal Infect Rep"},{"issue":"3","key":"5093_CR23","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/AAC.01222-09","volume":"54","author":"RE Lewis","year":"2010","unstructured":"Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP (2010) Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 54(3):1298\u20131304","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5093_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2396570","volume":"56","author":"M Liang","year":"2024","unstructured":"Liang M, Xu J, Luo Y, Qu J (2024) Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review. Ann Med 56(1):2396570","journal-title":"Ann Med"},{"key":"5093_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00489-18","author":"A L\u00f3pez-S\u00e1nchez","year":"2018","unstructured":"L\u00f3pez-S\u00e1nchez A, P\u00e9rez-Cantero A, Torrado-Salmer\u00f3n C, Martin-Vicente A, Garc\u00eda-Herrero V, Gonz\u00e1lez-Nicol\u00e1s M\u00c1 et al (2018) Efficacy, biodistribution, and nephrotoxicity of experimental amphotericin B-deoxycholate formulations for pulmonary aspergillosis. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00489-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement_2","key":"5093_CR26","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","volume":"77","author":"J Maertens","year":"2022","unstructured":"Maertens J, Pagano L, Azoulay E, Warris A (2022) Liposomal amphotericin B\u2014the present. J Antimicrob Chemother 77(Supplement_2):ii11\u2013ii20","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"5093_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s40475-020-00222-1","volume":"8","author":"B Morales-Franco","year":"2021","unstructured":"Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO, S\u00e1nchez-Nu\u00f1o YA, Davila-Villa P, Anaya-Ambriz EJ et al (2021) Host-pathogen molecular factors contribute to the pathogenesis of Rhizopus spp. in diabetes mellitus. Curr Trop Med Rep 8(1):6\u201317","journal-title":"Curr Trop Med Rep"},{"issue":"6","key":"5093_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11046-021-00584-8","volume":"186","author":"V Muthu","year":"2021","unstructured":"Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R (2021) Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 186(6):739\u2013754","journal-title":"Mycopathologia"},{"issue":"7","key":"5093_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/myc.13581","volume":"66","author":"II Osaigbovo","year":"2023","unstructured":"Osaigbovo II, Ekeng BE, Davies AA, Oladele RO (2023) Mucormycosis in Africa: epidemiology, diagnosis and treatment outcomes. Mycoses 66(7):555\u2013562","journal-title":"Mycoses"},{"key":"5093_CR30","doi-asserted-by":"crossref","unstructured":"Patel A, Kaur H, Xess I, Michael J, Savio J, Rudramurthy S et al (2020) A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin microbiol infect 26(7):944. e9-. e15","DOI":"10.1016\/j.cmi.2019.11.021"},{"issue":"9","key":"5093_CR31","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.3201\/eid2709.210934","volume":"27","author":"A Patel","year":"2021","unstructured":"Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R et al (2021) Multicenter epidemiologic study of coronavirus disease\u2013associated mucormycosis, India. Emerg Infect Dis 27(9):2349","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"5093_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010026","volume":"5","author":"H Prakash","year":"2019","unstructured":"Prakash H, Chakrabarti A (2019) Global epidemiology of mucormycosis. J Fungi 5(1):26","journal-title":"J Fungi"},{"issue":"3","key":"5093_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030523","volume":"9","author":"H Prakash","year":"2021","unstructured":"Prakash H, Chakrabarti A (2021) Epidemiology of mucormycosis in India. Microorganisms 9(3):523","journal-title":"Microorganisms"},{"issue":"5","key":"5093_CR34","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","volume":"41","author":"MM Roden","year":"2005","unstructured":"Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41(5):634\u2013653","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5093_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12223-021-00934-5","volume":"67","author":"A Sharma","year":"2022","unstructured":"Sharma A, Goel A (2022) Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol 67(3):363\u2013387","journal-title":"Folia Microbiol"},{"issue":"5","key":"5093_CR36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1017\/S0022215121000992","volume":"135","author":"S Sharma","year":"2021","unstructured":"Sharma S, Grover M, Bhargava S, Samdani S, Kataria T (2021) Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 135(5):442\u2013447","journal-title":"J Laryngol Otol"},{"issue":"1","key":"5093_CR37","first-page":"46","volume":"24","author":"A Sharma","year":"2024","unstructured":"Sharma A, Alam MA, Dhoundiyal S, Sharma PK (2024) Review on mucormycosis: pathogenesis, epidemiology, microbiology and diagnosis. Infectious Disorders-Drug TargetsDisorders 24(1):46\u201355","journal-title":"Infectious Disorders-Drug TargetsDisorders"},{"issue":"4","key":"5093_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040265","volume":"6","author":"A Skiada","year":"2020","unstructured":"Skiada A, Pavleas I, Drogari-Apiranthitou M (2020) Epidemiology and diagnosis of mucormycosis: an update. J Fungi 6(4):265","journal-title":"J Fungi"},{"issue":"4","key":"5093_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11046-020-00462-9","volume":"185","author":"G Song","year":"2020","unstructured":"Song G, Liang G, Liu W (2020) Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 185(4):599\u2013606","journal-title":"Mycopathologia"},{"issue":"9","key":"5093_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/nep.14070","volume":"27","author":"J Tan","year":"2022","unstructured":"Tan J, Liew A, Koh D (2022) Clinical outcomes and performance indicators of patients with kidney failure and acute kidney injuries in ASEAN countries. Nephrology 27(9):739\u2013752","journal-title":"Nephrology"},{"issue":"8","key":"5093_CR41","volume":"17","author":"V Verma","year":"2025","unstructured":"Verma V, Singh P, Gupta S, Karkhur S, Verma M (2025) Comparative analysis of outcomes and influencing factors in COVID-associated rhino-orbital-cerebral mucormycosis: globe salvage versus exenteration. Cureus 17(8):e90777","journal-title":"Cureus"},{"key":"5093_CR42","doi-asserted-by":"crossref","unstructured":"Wahab S, Muzammil K, Nasir N, ul Hasan A, Siddiqui Z, Aggarwal P et al (2021) Agents of mucormycosis outbreak associated with COVID-19. Ann Phytomedicine An Int J COVID 19","DOI":"10.54085\/ap.covid19.2021.10.2.5"},{"issue":"12","key":"5093_CR43","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","volume":"45","author":"TJ Walsh","year":"2001","unstructured":"Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45(12):3487\u20133496","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5093_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9040065","volume":"9","author":"F Yasmin","year":"2021","unstructured":"Yasmin F, Najeeb H, Naeem A, Dapke K, Phadke R, Asghar MS et al (2021) COVID-19 associated mucormycosis: a systematic review from diagnostic challenges to management. Diseases 9(4):65","journal-title":"Diseases"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05093-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:21:06Z","timestamp":1781511666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5093"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05093-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Fayoum University Faculty of Medicine Research Ethics Committee (Approval No. M 487).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this was a retrospective observational study based on the review of existing medical records, the requirement for written informed consent was waived by the institutional ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}